ArticleInternational journal of clinical oncology2026
Radiotherapy utilization in the last 30 days before death among patients with malignant neoplasms in Japan: a claims database study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRadiotherapy (RT) utilization in the last 30 days before death has been reported at 5-10%, but data from Japan are lacking. This study aimed to characterize patterns of end-of-life RT utilization among patients with malignant neoplasms in Japan.
methodsUsing the DeSC insurance claims database, patients who died between May 2016 and December 2024 with a primary malignant neoplasm diagnosis were identified. RT utilization in the last 30 days before death, treatment techniques, and the proportions of potentially excessive RT (IMRT, stereotactic irradiation, particle beam therapy, or ≥ 11 treatment days) and single-fraction RT were examined. Multivariable logistic regression was used to explore factors associated with RT utilization and single-fraction RT use.
resultsAmong 329,230 deceased patients, 8799 (2.7%) received RT in the last 30 days before death. Potentially excessive RT was observed in 33.7%, declining from 43.1% in 2016 to 27.2% in 2024. Single-fraction RT accounted for 5.5%, increasing from 2.8% in 2016 to 8.8% in 2024. On multivariable analysis, older age, higher comorbidity, and palliative care unit admission were associated with non-use of RT, while bone metastasis, higher-function hospitals, and urban location were associated with higher utilization. Bone metastasis, palliative care unit admission, and higher hospital function were associated with greater single-fraction RT use.
conclusionsThe end-of-life RT utilization rate in Japan was 2.7%, lower than rates reported in other countries. Potentially excessive RT showed a declining trend, while single-fraction RT showed an increasing trend. These findings provide baseline data for optimizing end-of-life RT practices in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.